Cidomycin 80 mg/2 ml Solution for Injection

Each ampoule or vial (2 ml) contains Gentamicin Sulphate Ph. Eur. equivalent to 80 mg Gentamicin base.

For the full list of excipients, see section 6.1.

Solution for Injection.

Clear, colourless solution.

Gentamicin is an aminoglycoside antibiotic with broad-spectrum bactericidal activity. It is indicated to treat severe infections caused by bacteria susceptible to gentamicin such as, but not limited to:

• Urinary tract infections

• Respiratory tract infections

• Intra-abdominal infections

• CNS infections

• Severe neonatal infections

It is usually active against most strains of the following organisms: Escherichia coli, Klebsiella spp., Proteus spp. (indole positive and indole negative), Pseudomonas aeruginosa, Staphylococci, Enterobacter spp., Citrobacter spp. and Providencia spp.

Consideration should be given to official local guidance on the appropriate use of antibacterial agents.

Posology

Adults

The recommended dose in adults with normal renal function is 3 – 5 mg/kg/day, depending on the severity of infection, administered as one single dose (preferred) or in two divided doses. The dose should be adjusted according to clinical response and serum concentration levels (see below). Dose calculations should be based on ideal body weight. A dosing frequency of more than twice daily may be adopted for some specific pathogens or some sites of infection as recommended in national and local guidance.

Once daily dosing is not recommended in cases of endocarditis, depending on the responsible pathogens. National and local guidance on treatment with gentamicin and serum level monitoring in endocarditis should be followed.

In patients with normal renal function, 160 mg once daily may be used for the treatment of urinary tract infections.

Paediatric population

The daily dose recommended in children aged 1 year and above and adolescents with normal renal function, is 3 – 6 mg/kg/day as one single dose (preferred) or two divided doses.

The daily dose in infants after the first month of life is 4.5 – 7.5 mg/kg/day as one single dose (preferred) or two divided doses.

The daily dose in neonates and pre-term infants (aged 0 – 4 weeks old) is 4 – 7 mg/kg/day. Due to the longer half-life, newborns are given the required daily dose in one single dose.

Elderly

There is some evidence that elderly patients may be more susceptible to aminoglycoside toxicity whether secondary to previous auditory/vestibular impairment or borderline renal dysfunction. Accordingly, therapy should be closely monitored by frequent determination of gentamicin serum levels, assessment of renal function and signs of ototoxicity.

Renal impairment

In impaired renal function, the recommended daily dose has to be decreased and adjusted to the renal function. This can be achieved by reducing the dose and/or increasing the dose interval.

In all patients with renal impairment, serum gentamicin peak and trough concentration and renal function must be monitored frequently (see below).

Nomograms are available for the calculation of dose, which depends on the patient's age, weight and renal function. Local guidance should be followed where available.

No clear recommendation can be made for once daily dosing; dosing should be guided by plasma concentration levels. In patients with moderate renal impairment, in whom once daily dosing would be considered appropriate if their renal function were normal, the dose interval should be at least 24 hours and extended according to the degree of renal impairment and the results of serum gentamicin monitoring. Limited data are available in patients with severe renal impairment (creatinine clearance < 30 ml/min) after once daily dose administration.

The following table may be useful for adults on multiple daily dose regimens:

*60 mg if body weight < 60 kg.

Monitoring advice

Regular serum concentration monitoring of gentamicin is recommended for all patients, and especially in the elderly, newborns, obesity and in patients with impaired renal function, as well as patients with cystic fibrosis. Gentamicin should not be prescribed if serum concentrations cannot be monitored.

There are no universally accepted guidelines for therapeutic drug monitoring of gentamicin. Local monitoring and dose adjustment guidelines should be followed where available.

Pre-dose (“trough level”) monitoring is recommended to ensure that the interval between doses is correct. Trough levels are measured at the end of a dosing interval and should not exceed 1 mg/L for once daily dosing or 2 mg/L for multiple daily dosing. Levels in excess of these indicate the need to extend the interval between doses, not reduction of the dose.

Post-dose (“peak level”) monitoring is recommended to check the adequacy of a dose or to ensure that it is not excessive and likely to cause toxicity. Peak levels should be measured one hour after an intravenous bolus or intramuscular bolus dose, or 30 minutes after the end of an infusion. A plasma concentration <4 mg/L indicates that the dose is likely to be inadequate and a dose increase should be considered; plasma concentrations >10 mg/L indicate an increased risk for toxicity, particularly ototoxicity, and a dose reduction should be considered.

Any change in dose should be re-assessed with pre- and post-dose levels to confirm the adequacy of the new dose and the appropriateness of the dose interval.

Method of administration

The recommended dose and precautions for intramuscular and intravenous administration are identical. Gentamicin when given intravenously should be injected directly into a vein or into the drip set tubing over no less than three minutes. If administered by infusion, this should be over 20 – 30 minutes and in no greater volume of fluid than 100 ml. Longer infusion times of up to 60 minutes may be used, in particular for a once daily dosing regimen. Once daily dosing should only be administered through the intravenous route.

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

• Myasthenia gravis.

Ototoxicity and nephrotoxicity

Ototoxicity has been reported following the use of aminoglycosides, including gentamicin. Symptoms include loss of balance and hearing loss, which may be irreversible (see section 4.8). Important risk factors include renal impairment, high doses, prolonged duration of treatment and age (neonates/infants and possibly the elderly). Due to the potential for ototoxicity and nephrotoxicity, monitoring of vestibule, cochlea and renal function is recommended before, during and shortly after treatment (see section 4.8). Serum levels are determined so as to avoid peak concentrations above 10 mg/L and troughs above 1 mg/L when administering gentamicin once daily and 2 mg/L when administering gentamicin twice daily.

As there is some evidence that risk of both ototoxicity and nephrotoxicity is related to the level of total exposure, duration of therapy should be the shortest possible compatible with clinical recovery. In some patients with impaired renal function there has been a transient rise in blood-urea-nitrogen which has usually reverted to normal during or following cessation of therapy. It is important to adjust the frequency of dosage according to the degree of renal function.

There have been observed cases of an increased risk of ototoxicity with aminoglycosides administered to patients with mitochondrial mutations, particularly the m.1555A>G mutation, including cases where the patient's aminoglycoside serum levels were within the recommended range. Some cases were associated with a maternal history of deafness and/or mitochondrial mutation. Mitochondrial mutations are rare, and the penetrance of this observed effect is unknown.

In cases of significant obesity gentamicin serum concentrations should be closely monitored and a reduction in dose should be considered. To avoid adverse events, continuous monitoring (before, during and after treatment) of hepatic and laboratory parameters is also recommended.

Gentamicin should only be used in pregnancy if considered essential by the physician (see section 4.6).

Gentamicin should be used with care in conditions characterised by muscular weakness.

Superinfection

Treatment with gentamicin may produce an excessive growth of drug-resistant micro-organisms. If this happens, an appropriate treatment should be initiated.

Pseudomembranous colitis

Diarrhoea and pseudomembranous colitis have been observed when gentamicin is combined with other antibiotics. These diagnoses should be considered in every patient that develops diarrhoea during or immediately after treatment. Gentamicin should be discontinued if the patient suffers severe diarrhoea and/or bloody diarrhoea during treatment and an appropriate treatment should be initiated. Drugs that inhibit peristalsis should not be administered (see section 4.8).

Severe subcutaneous adverse reactions (SCARs)

Serious skin reactions including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with gentamicin treatment. Patients should be informed about the signs and symptoms of serious skin manifestations and monitored closely. Treatment should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of skin hypersensitivity.

Excipient with known effect

Sodium: This medicine contains less than 1 mmol sodium (23 mg) per 2 ml vial or ampoule, that is to say essentially 'sodium-free'.

Ototoxicity and nephrotoxicity

Concurrent administration of gentamicin and other potentially ototoxic or nephrotoxic drugs should be avoided. Potent diuretics such as etacrynic acid and furosemide are expected to enhance the risk of ototoxicity whilst amphotericin B, cisplatin and ciclosporin are potential enhancers of nephrotoxicity.

Any potential nephrotoxicity of cephalosporins, and in particular cephaloridine, may also be increased in the presence of gentamicin. Consequently, if this combination is used monitoring of kidney function is advised.

Neuromuscular blockade

Neuromuscular blockade and respiratory paralysis have been reported from administration of aminoglycosides to patients who have received curare-type muscle relaxants during anaesthesia. Concomitant use of gentamicin with drugs with neuromuscular blocking effects, such as botulinum toxin, may increase the risk of toxicity due to enhanced neuromuscular block.

Aminoglycosides such as gentamicin can also act as neuromuscular blockers and may therefore antagonise the effects of neostigmine or pyridostigmine.

The following combinations with gentamicin may require dose adjustment:

• Concomitant use of indomethacin possibly increases plasma concentrations of gentamicin in neonates.

• Concomitant use with oral anticoagulants may decrease thrombin levels and increase the risk of bleeding.

• Concomitant use of bisphosphonates with gentamicin may increase the risk of hypocalcaemia.

Pregnancy

There are limited data from the use of aminoglycosides, including gentamicin, in pregnancy.

Gentamicin crosses the placenta, and there is a risk of ototoxicity (vestibulocochlear nerve damage) and/or renal damage in the fetus, as seen in animal studies (see section 5.3). Gentamicin should not be used in pregnancy, except in case of life-threatening situations where expected benefits outweigh possible risks.

In such cases, maternal serum gentamicin concentration monitoring is recommended (see section 4.2). Monitoring of the hearing and renal function of the infants is also recommended.

Breast-feeding

Gentamicin is excreted in human breast milk and was detected in low concentrations in the serum of breast-fed infants, except in cases where the mucous membrane of the infant's stomach and intestines is severely eroded.

In cases of suspected severe mucosal erosion, if the infant is breast-fed during gentamicin treatment, it is recommended to monitor the serum concentration of gentamicin in the infant (see section 4.2). Animal and human data suggest that if the serum gentamicin concentration in the infant exceeds 1 μg/ml either breast-feeding or the gentamicin therapy may need to be discontinued, under medical supervision.

The following effects of gentamicin on the infant's normal gastrointestinal flora are possible and it is recommended to monitor the infant for possible effects such as diarrhoea, candidiasis and bloody stools.

Not known.

The following CIOMS frequency rating is used, when applicable: Very common (≥ 1/10); common (≥ 1/100 to ≤ 1/10); uncommon (≥ 1/1,000 to ≤ 1/100); rare (≥ 1/10,000 to ≤ 1/1,000); very rare (≤ 1/10,000); not known (cannot be estimated from the available data).

Infections and infestations:

Not known: antibiotic-associated colitis (including pseudomembranous colitis), superinfection (caused by gentamicin-resistant bacteria)

Blood and lymphatic system disorders:

Not known: anaemia, blood dyscrasias

Immune system disorders:

Not known: hypersensitivity (see section 4.4), anaphylaxis/anaphylactic reaction (including anaphylactic shock)

Metabolism and nutrition disorders:

Not known: hypomagnesaemia on prolonged therapy

Psychiatric disorders:

Not known: depression, hallucinations, confusion

Nervous system disorders:

Not known: central neuropathy (including convulsions, lethargy, encephalopathy), peripheral neuropathy

Ear and labyrinth disorders:

Not known: vestibular damage, transitory hearing loss, irreversible hearing loss, deafness, particularly after exposure to ototoxic drugs or in the presence of renal dysfunction (see section 4.4).

Gastrointestinal disorders:

Very common: vomiting

Not known: stomatitis, nausea

Hepatobiliary disorders:

Not known: abnormal liver function, transaminases increased

Skin and subcutaneous tissue disorders:

Not known: Stevens-Johnson syndrome, toxic epidermal necrosis, rash, purpura, urticaria, pruritus

Renal and urinary disorders:

Very rare: acute renal failure, Fanconi-like syndrome in patients treated with a prolonged course of high dose

Not known: nephrotoxicity (usually reversible) has been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Haemodialysis and peritoneal dialysis will aid the removal from blood, but the former is probably more efficient. Calcium salts given intravenously have been used to counter the neuromuscular blockade caused by gentamicin.

Pharmacotherapeutic group: Anti-bacterials for systemic use, ATC Code: J01GB03

Gentamicin is a mixture of antibiotic substances produced by the growth of micromonospora purpurea. It is bactericidal with greater antibacterial activity than streptomycin, neomycin or kanamycin.

Gentamicin exerts a number of effects on cells of susceptible bacteria. It affects the integrity of the plasma membrane and the metabolism of RNA, but its most important effects is inhibition of protein synthesis at the level of the 30s ribosomal subunit.

Gentamicin is not readily absorbed from the gastro-intestinal tract. Gentamicin is 70 – 85% bound to plasma albumin following administration and is excreted 90% unchanged in urine. The half-life for its elimination in normal patients is 2 – 3 hours.

• Effective plasma concentration is 4 – 8 µg/ml.

• The volume of distribution (vd) is 0.3 L/kg.

• The elimination rate constant is:

1. 0.02 hr^-1 for anuric patients*

2. 0.30 hr^-1 normal

*Therefore, in those with anuria care must be exercised following the usual initial dose, any subsequent administration being reduced in-line with plasma concentrations of gentamicin.

Paediatric population (premature infants and neonates)

Distribution

The distribution volume of gentamicin is about equivalent to the volume of extracellular water. In the newborn water makes up 70 – 75% of bodyweight, compared with 50 – 55% in adults. The extracellular water compartment is larger (40% of body weight compared with 25% of body weight in adults). Therefore, the volume of distribution of gentamicin per kg bodyweight is affected and decreases with increasing age from 0.5 – 0.7 L/kg for a premature newborn to 0.25 L/kg for an adolescent. The larger volume of distribution per kg bodyweight means that for adequate peak blood concentration a higher dose per kg bodyweight needs to be administered.

Elimination

Gentamicin is not metabolized in the body but is excreted unchanged in microbiologically active form predominantly via the kidneys. In patients with normal renal function the elimination half-life is about 2 – 3 hours. In neonates, elimination rate is reduced due to immature renal function.

Elimination half-life averages approximately 8 hours in neonates at a gestational age of 26 – 34 weeks compared with about 6.7 hours in neonates at a gestational age of 35 – 37 weeks.

Correspondingly, clearance values increase from about 0.05 L/h in neonates at a gestational age of 27 – 0.2 L/h in neonates at a gestational age of 40 weeks.

Reproductive and developmental toxicity

The limited non-clinical literature mentions that prenatal or postnatal administration of gentamicin to rodents and guinea pigs produces developmental toxicity of the kidney and/or inner ear in fetuses and offspring.

Sodium chloride

Water for Injections

2N Sodium Hydroxide (for pH adjustment)

2N Sulphuric Acid (for pH adjustment)

In general, gentamicin injection should not be mixed.

In particular the following are incompatible in mixed solution with gentamicin injection:

- penicillins

- cephalosporins

- erythromycin

- heparins

- sodium bicarbonate

*Dilution in the body will obviate the danger of physical and chemical incompatibility and enable gentamicin to be given concurrently with the drugs listed above either as a bolus injection into the drip tubing, with adequate flushing, or at separate sites. In the case of carbenicillin, administration should only be at a separate site.

*Carbon dioxide may be liberated on addition of the two solutions. Normally this will dissolve in the solution but under some circumstances small bubbles may form.

3 years

Do not store above 25°C. Do not refrigerate or freeze.

Cidomycin is supplied in in packs of 5 x 2 ml colourless glass ampoules (Type I) with an OPC (one point cut) break system and red and green rings or in packs of 5 x 2 ml colourless glass vials (Type I) closed with a chlorobutyl rubber stopper sealed with an aluminium capsule type flip-off.

Not all pack sizes may be marketed.

No special requirements.

Mercury Pharmaceuticals Ltd,

Capital House,

85 King William Street,

London

EC4N 7BL, UK

PL 12762/0681

Date of first authorisation: 27 July 2011

21 April 2023

LEGAL CLASSIFICATION

POM